2025-05-06-Jefferies-福泰制药（VRTX）_电话会议的五个要点_-_Journavx_Rx高于第三方数据所示_16页_1mb

Vertex (VRTX) Summary

Core Content

Vertex (VRTX) is a biotechnology company with a strong focus on cystic fibrosis (CF) and a diverse pipeline in other therapeutic areas. The report highlights key developments, financial performance, and future outlook for the company, emphasizing its potential for growth and the importance of upcoming clinical data.

Main Points

1. Journavx (Suzetrigine) Acute Pain Sales

• Journavx prescriptions have shown strong growth, with +20% week-over-week (w/w) increase, surpassing third-party data.
• As of April 25, 2025, ~25,000 scripts have been written, indicating +5,000 w/w growth.
• The company estimates that ~9,000 scripts per week are needed to reach the $85M consensus by year-end.
• Reimbursement and payor coverage are improving, which is expected to drive sales in the second half of the year.

2. Financial Performance

• Q1 2025 total CF revenues were $2.76B, slightly below the consensus of $2.85B.
• EPS was $4.06, lower than the consensus of $4.28, due to slightly higher operating expenses.
• The company raised the revenue guidance for 2025 to $11.85-$12.0B, with consensus already at the top end of this range.

3. Pipeline Highlights

• Phase III DPN chronic pain data is expected in 2026, with potential to move the stock $575-650 if positive.
• Phase II VX-993 acute pain data is expected in H2 2025, with enrollment completing in Q2.
• Phase III inaxaplin for APOL1 kidney disease is also expected in 2026.
• Phase III VX-880 for T1D is expected to complete enrollment in Q2 2025, with a potential regulatory filing in 2026.
• Phase III povetacicept for IgAN is expected to have interim data in H1 2026.

4. Risk and Reward

• The company has low earnings visibility and no major clinical trial binary risk in 2025.
• Medicaid and MFN risk are significant concerns, with a 20% Medicaid exposure.
• The report outlines three major catalysts in 2026: DPN chronic pain, APOL1 kidney disease, and IgAN povetacicept.
• Price targets are set at $575 (+15%) and $650 (+30%), with the latter based on better-than-expected pipeline data.

5. Investment Thesis

• VRTX is viewed as a core defensive large cap biotech holding.
• The company is expected to continue executing and beat/raise due to its strong CF base business and new triple-pill regimen.
• The SOTP valuation supports $325/sh for CF base business, $60/sh for cash, and $190/sh for pipeline value.
• The upside scenario assumes better pipeline data and includes $300/sh for CF base business, $60/sh for cash, and $290/sh for pipeline value.

Key Information

• Target Price: $500.19
• Price Target: $575 (+15%) and $650 (+30%)
• 52-Week High-Low: $519.88 - $377.85
• Market Cap: $129.8B
• Float: 98.7%
• Revenue Guidance for 2025: $11.85-$12.0B
• Non-GAAP OpEx Guidance for 2025: $4.9-$5.0B
• IPR&D Expenses: $100M

Catalysts

Sustainability Matters

• Access and Affordability: VRTX is a key player in CF treatment, aiming to increase access in lower-income countries.
• Product Quality and Safety: Ensuring regulatory compliance and patient safety is critical for both revenue and trust.

ESG Sector Deep Dives

• US Biotech, Pharma, and Specialty Pharma sectors are highlighted as key areas for VRTX's impact.

Financials & Pipeline Updates

• CF Royalty: Estimated at $15/sh, expected to increase as Alyftrek sales ramp up.
• Alyftrek Sales: Lower than consensus at $54M in Q1 2025, with a once-daily oral regimen and lower royalty burden.
• Casgevy (gene editing for SCD): Sales were $14M vs consensus of $15M, with significant potential for growth.
• Povetacicept: Shows 66% UPCR reduction at 48 weeks and eGFR stabilization.
• VX-993: Enrolling in Phase II acute pain study, with potential to combine with Nav1.7.
• VX-880: Phase III enrollment expected in Q2 2025, with a potential insulin independence endpoint.

Summary

Vertex is a leading biotech company with a strong CF business and a robust pipeline. Despite Q1 2025 being lighter than expected, the company remains a core holding due to its potential for growth in 2026. Key catalysts include Phase III data for DPN chronic pain, APOL1 kidney disease, and IgAN povetacicept, which could drive the stock price up to $575-650. The company is also focused on improving access and affordability for its treatments and maintaining product quality and safety.